biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Post by Sir_Holleron Jul 02, 2015 10:51am

149 Views

Post# 23886291

Aug 29

The $1.20 warrants expire on Aug 29 and BTI may only have about $1 million left.
Will we get those exercised.

BTI has said that it was looking to license the Hunter's Syndrome program or take it into the clinic with Dr. Scarpa in Europe. Will we get "remarkable" results and a decision to advance the program with Scarpa shortly? Does Scarpa have the ability to swing some funding for a Phase I program?

Bullboard Posts

How one company is disrupting PoC testing